Hereditary pheochromocytoma/paraganglioma syndrome with a novel mutation in the succinate dehydrogenase subunit B gene in a Japanese family: two case reports

Pheochromocytoma (PCC) and paraganglioma (PGL) are rare neuroendocrine tumors arising from the chromaffin cells of the adrenal medulla and extra-adrenal autonomic paraganglia, respectively. Up to 40% of patients with PCC/PGL (PPGL) carry a germline mutation [1]. To date, over 19 types of susceptibility genes for PPGL, including SDHA, SDHB, SDHC, SDHD, RET, VHL, NF1, TMEM127, and MAX have been reported [2]. Of these, succinate dehydrogenase (SDH)-related PPGLs are called hereditary pheochromocytoma/paraganglioma syndrome (HPPS).

In particular, SDHB mutations are important because they are highly associated with the malignant behavior of PPGL [3‐7]. SDHB encodes one of four subunits of mitochondrial complex II (SDH). Consistent with Knudson’s two-hit hypothesis, the function of complex II is lost by biallelic inactivation (typically resulting from one inherited and one somatic event) of SDHB, resulting in increased reactive oxygen species levels, hypoxia-inducible factor-α (HIF-1α) activation, and pseudohypoxia, which promote tumor formation and catecholamine oversecretion [3, 8‐12]. Therefore, patients with HPPS should be actively tested for SDHB mutations, and information on a novel mutation should be reported. Herein, we report a family of HPPS with a novel SDHB mutation, c.424-2delA.

Patient 1. Daughter (III-2, proband): A 19-year-old Japanese woman was diagnosed with hypertension (200/140 mmHg) at a physical examination. The following month, she visited an emergency hospital with complaints of palpitation and dyspnea. Abdominal computed tomography (CT) revealed a 50 mm mass above the left kidney (Fig. 1a). Her blood catecholamine levels were elevated. Her father had died owing to multiple metastases of PGL when he was 50 years old (Fig. 2). She was suspected of having PPGL and was referred to our hospital for further examination.

The patient’s consciousness was clear. A physical examination revealed the following findings: body temperature, 37.4 °C; blood pressure, 115/73 mmHg; and pulse rate, 95 bpm. She was 152 cm in height with a body weight of 48 kg (body mass index, 20.8 kg/m²). Hypertensive fundus changes (H1S1/H1S1) were observed. Heart sound was regular, and a Levine II/VI systolic murmur was heard along the left sternal border. The abdomen was flat and soft, and the mass was not palpable.

The patient’s laboratory data are presented in Table 1, which indicates excessive catecholamine production. Abdominal magnetic resonance imaging (MRI) showed that the mass was nonhomogeneous and moderate in intensity on T2-weighted images (Fig. 1b). ¹²³I-metaiodobenzylguanidine (MIBG) scintigraphy showed no accumulation in the mass (Fig. 1c). ¹⁸F-fluorodeoxyglucose-positron emission tomography (FDG-PET) showed accumulation (maximum standardized uptake value 10.9) in the mass (Fig. 1d). Based on these results, she was diagnosed with left PCC or abdominal PGL. She was prescribed doxazosin (up to 20 mg/day) preoperatively for alpha blockade.

She underwent a laparoscopic left adrenalectomy. The weight of the tumor mass was 48.5 g (50 × 40 × 25 mm). A pathological investigation confirmed the diagnosis of retroperitoneal PGL (Fig. 3 a, b). The grading system for adrenal pheochromocytoma and paraganglioma (GAPP) score was 6 points, suggesting a tumor with intermediate-grade malignancy [13]. Immunohistochemical (IHC) staining of SDHA yielded positive results, and IHC staining of SDHB yielded negative results, suggesting an SDHB, SDHC, or SDHD mutation [14, 15] (Fig. 3c). We performed genetic testing for SDHB with written consent from the patient and her mother. We extracted the germline DNA from her peripheral blood and screened the eight exons of the SDHB gene. The results of polymerase chain reaction (PCR)-direct sequencing method, conducted as described previously [16], showed that she had heterozygous germline mutations in the SDHB intron 4/exon 5 junction (c.424-2delA) (Fig. 4). This mutation is predicted to constitute a splice acceptor site using splice site prediction [17] and NetGene2 [18]. Therefore, it can lead to missplicing, such as exon skipping, activation of a cryptic splice site, or intron retention, resulting in the production of abnormal proteins [19]. In addition, in silico analysis, using MutationTaster [20], predicted this mutation was “disease causing.” Sequencing analysis of the PGL tissue showed loss of the wild-type T allele, suggesting loss of heterozygosity (LOH) (Fig. 4). After surgery, her blood pressure normalized, and the plasma and urinary catecholamine levels were within the normal range. We are performing a close follow-up with biannual medical examinations, biochemical tests, MRI of the abdomen, and an annual MRI from the neck to the pelvis. No recurrence or metastasis has been observed 4 years since surgery.

Patient 2. Father (II-2): A 40-year-old Japanese man (father of patient 1) had back pain and was examined by MRI 11 years before the first visit of the daughter. An abdominal mass with low intensity on the T1-weighted image and high intensity on the T2-weighted image, and a mass on the seventh rib, were found. An endocrinological examination showed that dopamine in a 24-hour urine collection was as high as 1006.3 μg/day. Adrenaline and noradrenaline levels were within the normal range. ¹²³I-MIBG scintigraphy showed no accumulation. He was considered to have a retroperitoneal tumor and metastasis to the rib. The patient underwent total resection of the retroperitoneal tumor and was pathologically diagnosed with retroperitoneal PGL (10 × 7 × 4 cm) (Fig. 3d). Although chemotherapy with cyclophosphamide, vincristine, and dacarbazine, and radiation therapy for rib metastasis, were performed, tumor recurrence in the pelvis was found when he was 46 years old. The tumor was resected and diagnosed pathologically as recurrent retroperitoneal PGL (55 × 50 mm). Later, hepatic metastasis and pleural dissemination were observed, and partial lobectomy of the liver and ¹³¹I-MIBG therapy were performed. However, the treatment was not effective, and he passed away when he was 50 years old.

After the daughter was diagnosed with PGL, we added a further study to the surgical specimen of the primary and recurrent PGL of the father. The GAPP score of the primary PGL was 3 points, suggesting the tumor was an intermediate-grade malignancy [13]. IHC staining of SDHB of the primary PGL was negative (Fig. 3e). SDHB genetic testing revealed that both primary and recurrent PGLs harbored the mutation c.424-2delA, which is the same as the PGL of the daughter (Fig. 4). The primary PGL tissue DNA showed c.424-2delA in heterozygosity, whereas the recurrent PGL tissue DNA showed loss of the wild-type T allele, suggesting LOH.

Although our two cases had the same SDHB mutation, phenotypes such as the age of onset, biochemical phenotype, and metastasis were different (Table 2). The son of patient 2 (III-1) might have the same SDHB mutation, given his family history; however, he did not provide consent to undergo genetic testing.

As the SDHB mutation is strongly associated with the malignant behavior of PPGL, performing genetic testing in patients with PPGL suspected of harboring SDHB mutations is important. Identification of a novel disease causing SDHB mutation may contribute to expanding our knowledge about PPGL and facilitate more patient-tailored management. To date, 289 unique SDHB mutations have been described [21]. Most germline mutations are randomly distributed over SDHB, and at least two hot spots have been described [22‐24]. Germline SDHB mutations are inherited in an autosomal dominant manner, and their penetrance is approximately 20% by age 50 years and 40% by age 70 years [24‐26]. The phenotype of PPGL with SDHB mutation is often characterized as metastatic, with extra-adrenal development (especially abdominal PGL), and multiple and early onset [3, 14]. Therefore, SDHB genetic testing should be performed in patients with PPGL who have these characteristics or a family history of PPGL. In the present cases, as the daughter had early-onset abdominal PGL with a family history of metastatic PGL, SDHB mutation was strongly suspected. In addition, a false-negative ¹²³I-MIBG scintigraphy, as observed in the daughter, is frequently associated with SDHB mutations [27]. SDHB genetic testing identified the novel splice-site mutation c.424-2delA in her germline, PGL tissue, and her father’s primary and recurrent PGL tissue. In silico analysis predicted this mutation was “disease causing.” As for her PGL and the recurrent PGL of her father, LOH of SDHB was suggested, which indicated tumor formation by biallelic inactivation of SDHB. To the best of our knowledge, this is the first report showing that the SDHB mutation c.424-2delA is responsible for PPGL [21, 28].

Multiple cases of different phenotypes within the same family with the same SDHB mutation have been reported [4, 16, 29]. These different phenotypes may be due to the involvement of several disease-related genes and the variation in epigenetic changes. Many reports have indicated there is no genotype–phenotype correlation in the SDHB mutant PPGL [23, 25, 30]. However, Andrews et al. reported that a specific missense mutation in SDHB (p.Ile127Ser) could have a marked effect on protein structure, resulting in increased penetrance and risk of PPGL [31], suggesting the possibility of genotype–phenotype correlation in SDHB mutation. Further investigation of genotype–phenotype correlation may advance our knowledge about individual treatment and surveillance screening based on genotype.

Our cases indicate the importance of surveillance screening in SDHB mutation carriers, although there is no widely agreed consensus regarding optimal surveillance for asymptomatic carriers and those in whom the presenting tumor has been resected. Surveillance screening in SDHB mutation carriers enables early detection and timely resection of SDHB-associated tumors, reducing the risk of metastatic disease [32]. In our cases, if SDHB genetic testing had been performed on the father with metastatic PGL, and SDHB mutation had been identified, surveillance screening might have revealed the PGL in the daughter before it became secretory and/or symptomatic. The Endocrine Society recommends lifelong follow-up for all patients with PPGL [33]. The European Society of Endocrinology recommends follow-up for at least 10 years after surgery in all patients with PPGL and lifelong follow-up, especially for patients at high risk of recurrence (young patients and those with a genetic disease, a large tumor, and/or a PGL) [34]. However, there is no official guideline for the surveillance screening of patients with SDHB mutations. Some reported ideas of surveillance screening in SDHB mutation carriers are presented in Table 3 [4, 32, 35‐37]. We are performing a close follow-up on the daughter, considering she has developed PGL and her father had taken an aggressive course. All first-degree relatives are recommended to undergo targeted SDHB genetic testing of the proband’s mutation with genetic counseling; however, children should be offered testing if they are recommended surveillance [36, 37]. We recommended targeted SDHB genetic testing to her older brother (III-1), but he did not provide consent to undergo genetic testing.

In conclusion, we detected a novel SDHB mutation, c.424-2delA, in a Japanese family afflicted with HPPS and found the mutation to be responsible for HPPS. Since SDHB mutation is associated with the malignant behavior of PPGL, it is important to perform genetic testing for patients suspected of harboring the SDHB mutation (that is, metastatic, extra-adrenal, multiple, early onset, and family history of PPGL) and offer surveillance screening to mutation carriers.